Laboratory of Lymphomagenesis and Humanized Mouse Models

Core Lead: Giorgio Inghirami, MD 
Among our goals, we intend to: 1) provide investigators with PDX tumors with relevant genomic and RNA-Seq characterization data, as well as any technical information and advice; 2) conduct preclinical studies with PDX tumor models, both tumor specific and/or covering multiple tumor type; 3) identify predictive biomarkers to better select appropriate treatments for specific cancer patient populations; 4) Define the genomic landscape of naive and treated PDX to identify genomic aberration linked/predictive of clinical responses.
MCL-RI Grant 180078-01 LLS

Core Lead: Giorgio Inghirami, MD 

To procure patient specimens, characterize and assess the specimens as required by projects and for clinical trials, provide data to the projects and other cores, bank tissue, and distribute tissue to the projects.

Core Lead: Giorgio Inghirami, MD 
The pre-clinical models and therapeutics core (PMTC) will assemble and characterize the reagents critical for this proposal including the wide array of clinically and molecularly annotated primary pathological samples, patient derived tumor xenograft (PDTX) models as well as patient derived organoids (PDO).
P01CA229100

Core Lead: Giorgio Inghirami, MD 
The ultimate goal of this P01 is to compare and contrast the impact of mutations in CTCF and cohesin regulatory proteins with the effect of mutant or deregulated oncogenic transcription factors (such as NOTCH1), histone-modifying enzymes (Polycomb and CREBBP/EP300), as well as enzymes that control DNA methylation (DNMT3A).
P01 CA229086

PI: Giorgio Inghirami, MD 
To define the therapeutic efficacy of CD137L-CAR-T in colon cancer preclinical models.
CTSC 2020-2021  

Co-PI: Giorgio Inghirami, MD 
The goal of this infrastructure grant is to establish and maintain a cohort of over 12,000 non-Hodgkin lymphoma (NHL) patients to support broad and cutting-edge research that identifies clinical (including co-morbid diseases), epidemiologic (including lifestyle and other exposures), host genetic, tumor, and treatment factors, as well as the interaction among these factors, on short and long-term outcomes.
U01 CA195568-01

Core Lead: Giorgio Inghirami, MD 
The Preclinical Models and Therapeutics Core will continue to facilitate xenografting, cell line development and organoid generation from primary specimens of peripheral T-cell lymphoma (PTCL).  The central aim of the core is to provide the Projects and larger PTCL research community with tractable models for discovery biology and therapeutic validation.  This includes models of acquired resistance, both from patients after therapeutic failure and upon drug exposure within preclinical models.
7026-21 LLS SCOR 

Co-PI: Giorgio Inghirami, MD 
To define the role of the host in lymphoma progression and response to therapy.
R01 CA242069-01A1

PI: Giorgio Inghirami, MD
Vividion Therapeutics

PI: Giovanni Medico, MD
American Italian Cancer Foundation